Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ: INZY )

1.370 +0.020 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inozyme Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers FOXO Technologies Inc. (NYSE: FOXO) shares jumped 109% to $1.07. Akanda Corp. (NASDAQ: AKAN) rose 59% to $0.4459 after jumping 47% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
US Stocks Higher; Dow Rises 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 50 points on Friday. Following the market opening Friday, the Dow traded up 0.47% to 34,107.87 while the NASDAQ rose 0.55% to... 
Via Benzinga
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
Via Benzinga
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
From Inozyme Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nuvalent (NASDAQ:NUVL) stock increased by 15.9% to $25.5 during Friday's pre-market session. The company's market cap stands at $1.2 billion. 
Via Benzinga
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
Gold Prices Settle Lower; Vascular Biogenics Shares Plummet
U.S. stocks traded mostly higher toward the end of trading, with the S&P index gaining around 0.5% on Wednesday. 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
Tech Shares Move Higher, Nasdaq Jumps 200 Points
U.S. stocks traded higher midway through trading, with the NASDAQ Composite gaining more than 200 points on Wednesday. 
Via Benzinga
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year... 
Via Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2022
Upgrades 
Via Benzinga
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
2 Stocks Under $5 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Cyngn Inc. (NASDAQ: CYN) shares jumped 96.3% to close at $2.12 on Thursday after the company announced the official launch of DriveMod Kit, a turnkey autonomous vehicle... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 200 Points; United Airlines Shares Jump
U.S. stocks turned lower toward the end of trading, with the Nasdaq dropping 200 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Turns Negative; US Weekly Jobless Claims Edge Lower
U.S. stocks pared gains midway through trading, with the Nasdaq Composite dropping around 50 points on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.